No single best diet
Most named diets converge once calories, support, and adherence are matched.
This page compresses three linked questions: which diets actually help maintain a deficit, which anti-obesity medications are strong enough to change the game, and which supplements are merely modest helpers. The broad answer is that diet labels matter less than appetite suppression, decision reduction, and maintenance planning.
The real difference is not keto versus Mediterranean. It is ordinary lifestyle-only approaches versus modern anti-obesity drugs, and within lifestyle approaches it is structure-heavy plans versus improvising every meal.
Meal replacements and higher-protein eating look more useful than internet discourse admits because they reduce drift and preserve lean mass.
Intermittent fasting as a special mechanism, and OTC supplements as if they were small Ozempics. Most supplement effects live at the margin.
Most named diets converge once calories, support, and adherence are matched.
Tirzepatide and semaglutide are in a different effect-size class from supplements or ordinary diet tweaks.
Psyllium and structured protein tools can help. Most fat-burner discourse is marketing noise.
The hard part is not just losing weight. It is preventing rebound after the aggressive phase or after stopping medication.
Search across diets, medications, and supplements. The useful split is by function: structure tools, satiety tools, modern high-effect drugs, and marginal helpers.
Fast comparison of what each class seems to buy you. This is the part that is usually buried under diet ideology and supplement marketing.
| Class | Typical effect size | What it is really good for | Main limitation |
|---|---|---|---|
| Tirzepatide | `-15.0%` to `-20.9%` at 72 weeks; stronger than semaglutide in direct comparison | Strongest routine appetite suppression and highest routine weight-loss efficacy | Cost, GI effects, injection, regain after stopping |
| Semaglutide 2.4 mg | `-14.9%` to `-15.2%` in flagship trials | Major-effect option with obesity-specific cardiovascular-outcomes evidence | Still substantial regain after discontinuation |
| Retatrutide / frontier agents | High-upside but investigational; not a routine practical option yet | Most important pipeline category to watch | Status and access; should not be treated as interchangeable with approved drugs |
| Total diet replacement / VLCD | About `-7.2 kg` vs usual care at 12 months in DROPLET; larger short-term intensive losses possible | Strong reset and hard structure | Needs follow-up and an exit plan |
| Meal replacements | About `-1.44` to `-6.13 kg` extra at 1 year depending on support | Reducing decision fatigue | Monotony, weak if support collapses |
| High-protein | About `-0.79 kg` extra, plus lean-mass preservation benefits | Satiety and body-composition quality during a cut | Extra scale loss is modest |
| Psyllium / soluble fiber | Small helper effect; credible but not large | Pre-meal fullness and low-fiber diet support | GI tolerance, water requirement, modest payoff |
| Green tea / caffeine / berberine tier | Usually small or borderline-clinically-important effects | Minor marginal help for some users | Easy to oversell; side effects can erase the gain |
This is the compressed judgment call from the research, not just a stack of citations.
The main markdown files behind this page. This webapp is a compression layer over the saved research.